結核診断薬市場：検査タイプ、タイプ、エンドユーザー別-2025年～2030年の世界予測

結核診断薬市場は、2023年に30億1,000万米ドルと評価され、2024年には31億7,000万米ドルに達すると予測され、CAGR 5.48％で成長し、2030年には43億8,000万米ドルに達すると予測されています。

結核診断の範囲には、結核菌感染の特定を目的とした様々な検査や処置が含まれます。これには、喀痰顕微鏡検査、培養検査のような従来の方法、核酸増幅検査（NAAT）のような新しい分子診断が含まれます。効果的な結核診断の必要性は、感染症による死因の第一位である結核の世界の重荷によって強調されています。初期診断や治療反応のモニタリングから薬剤感受性試験まで、その用途は多岐にわたる。最終用途には病院、診断研究所、研究機関などが含まれ、臨床と公衆衛生の両方の視点が重視されています。

市場の洞察によると、技術的進歩、結核蔓延率の上昇、ヘルスケアインフラの改善が成長の主な要因となっています。特に、分子診断への急速な移行は、従来の方法と比較して精度が高く、結果が早いことが拍車をかけています。潜在的なビジネスチャンスは、結核の有病率は高いもの、診断施設が限られている新興国にあります。そこでは、政府の保健衛生イニシアティブとの提携により、市場拡大が期待できます。しかし、高度な診断にかかるコストが高いこと、結核菌の種類によって精度にばらつきがあること、低所得地域では認知度が低いことなどが大きな課題となっています。

技術革新の余地がある分野としては、迅速で信頼性の高い結果が得られる、費用対効果の高いポイントオブケア診断ツールの開発が挙げられます。これらは、特に農村部や資源に制約のある環境において、結核診断に革命をもたらす可能性があります。さらに、薬剤耐性結核菌の検出方法の調査は、多剤耐性結核との闘いに不可欠なブレークスルーをもたらす可能性があります。

同市場は、国内外に多数のプレーヤーが存在するため断片的な性質が支配的であり、企業は製品の差別化と戦略的提携に投資することで成功を収めることができます。NGOや公衆衛生プログラムとのコラボレーションは、市場への浸透とアウトリーチ活動を強化することができます。これらの促進要因を特定し、的を絞った調査と戦略的プランニングを通じて限界に対処することが、結核診断薬市場の持続的成長につながります。

市場力学：急速に進化する結核診断薬市場の主要な市場インサイトを解明

結核診断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の結核の負担増と早期診断の必要性
  • 研究開発投資の増加とパイプラインにある診断薬製品の集中化
  • 新興市場における政府の支援策と意識の高まり
• 市場抑制要因
  • 結核診断薬に関連する高コスト
  • 限られた償還オプション
• 市場機会
  • 政府による啓発プログラムの増加
  • 診断方法の進歩
• 市場の課題
  • 新興市場における保険適用率の低さ、または保険の不在

ポーターの5つの力結核診断薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：結核診断薬市場における外部からの影響の把握

外部マクロ環境要因は、結核診断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析結核診断薬市場における競合情勢の把握

結核診断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス結核診断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、結核診断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨結核診断薬市場における成功への道筋を描く

結核診断薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 結核の負担は世界的に増加しており、早期診断の必要性が高まっています。
    • 研究開発投資の増加とパイプラインにおける集中診断製品
    • 政府の支援的な取り組みと新興市場における意識の高まり
  • 抑制要因
    • 結核診断薬に関連する高コスト
    • 払い戻しオプションが限られている
  • 機会
    • 政府の啓発プログラムの増加
    • 診断手順の進歩
  • 課題
    • 新興市場では保険の適用範囲が狭い、または保険が存在しない
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 結核診断薬市場：検査タイプ別

• 薬剤感受性試験
• 実験方法
• マントーテスト
• 核酸検査
• 放射線撮影法

第7章 結核診断薬市場：タイプ別

• ポイントオブケアテクノロジー
• 迅速検査

第8章 結核診断薬市場：エンドユーザー別

• 診断調査室
• 病院・クリニック

第9章 南北アメリカの結核診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の結核診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの結核診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• ACON Laboratories, Inc.
• Becton, Dickinson, and Company
• bioMerieux SA
• Bruker Corporation
• Cepheid
• Elisabeth Pharmacon, spol. s r.o.
• ELITech Group
• F. Hoffmann-La Roche AG
• Hologic Corporation
• OSANG HEALTHCARE CO., LTD
• PerkinElmer, Inc.
• Siemens AG
• Thermo Fisher Scientific, Inc.
• Turklab A.S.

LIST OF FIGURES

• FIGURE 1. TUBERCULOSIS DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. TUBERCULOSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. TUBERCULOSIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. TUBERCULOSIS DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. TUBERCULOSIS DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG-SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LABORATORY METHODS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MANTOUX TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY RADIOGRAPHIC METHODS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS RESEARCH LABORATORY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 29. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 46. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 49. INDIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 101. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 113. POLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 116. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
• TABLE 146. TUBERCULOSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. TUBERCULOSIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Tuberculosis Diagnostics Market was valued at USD 3.01 billion in 2023, expected to reach USD 3.17 billion in 2024, and is projected to grow at a CAGR of 5.48%, to USD 4.38 billion by 2030.

The scope of Tuberculosis (TB) Diagnostics encompasses various tests and procedures aimed at identifying Mycobacterium tuberculosis infection. This includes traditional methods like sputum microscopy, culture tests, and newer molecular diagnostics such as nucleic acid amplification tests (NAATs). The necessity for effective TB diagnostics is underscored by the global burden of tuberculosis, which remains a leading cause of death from an infectious disease. Applications stretch from initial diagnosis and monitoring of treatment response to drug susceptibility testing. End-use sectors include hospitals, diagnostic laboratories, and research institutions, emphasizing both clinical and public health perspectives.

Market insights reveal that technological advancements, rising TB prevalence, and improved healthcare infrastructure are primary growth influencers. Particularly, the rapid switch to molecular diagnostics is spurred by their higher accuracy and faster results compared to conventional methods. Potential opportunities lie in emerging economies where TB prevalence is high but diagnostic facilities remain limited. There, partnerships with government health initiatives could expand market reach. However, high costs associated with advanced diagnostics, varied accuracy across different TB strains, and limited awareness in low-income regions pose significant challenges.

Innovation areas ripe for exploration include the development of cost-effective, point-of-care diagnostic tools that offer rapid and reliable results. These could revolutionize TB diagnostics, especially in rural and resource-constrained settings. Moreover, research into drug-resistant TB detection methods could provide essential breakthroughs in combating multi-drug resistant tuberculosis.

As the market predominantly displays a fragmented nature due to numerous local and international players, businesses can succeed by investing in product differentiation and strategic collaborations. Collaboration with NGOs and public health programs can enhance market penetration and outreach efforts. Identifying these drivers and addressing the limitations through targeted research and strategic planning can lead to sustained growth in the tuberculosis diagnostics market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tuberculosis Diagnostics Market

The Tuberculosis Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing burden of tuberculosis globally and need to diagnose at very early stage
  • Increasing R&D investments and intensive diagnostics products in pipelines
  • Supportive government initiatives and rising awareness in the emerging markets
• Market Restraints
  • High costs associated with tuberculosis diagnostics
  • Limited reimbursement options
• Market Opportunities
  • Rising number of government awareness programs
  • Advancement in the diagnostics procedures
• Market Challenges
  • Low coverage or absence of insurance in emerging markets

Porter's Five Forces: A Strategic Tool for Navigating the Tuberculosis Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tuberculosis Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tuberculosis Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tuberculosis Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tuberculosis Diagnostics Market

A detailed market share analysis in the Tuberculosis Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tuberculosis Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tuberculosis Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Tuberculosis Diagnostics Market

A strategic analysis of the Tuberculosis Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Tuberculosis Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ACON Laboratories, Inc., Becton, Dickinson, and Company, bioMerieux SA, Bruker Corporation, Cepheid, Elisabeth Pharmacon, spol. s r.o., ELITech Group, F. Hoffmann-La Roche AG, Hologic Corporation, OSANG HEALTHCARE CO., LTD, PerkinElmer, Inc., Siemens AG, Thermo Fisher Scientific, Inc., and Turklab A.S..

Market Segmentation & Coverage

This research report categorizes the Tuberculosis Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Test Type, market is studied across Drug-susceptibility Testing, Laboratory Methods, Mantoux Test, Nucleic Acid Testing, and Radiographic Methods.
• Based on Type, market is studied across Point-of-Care Technologies and Rapid Test.
• Based on End_User, market is studied across Diagnostics Research Laboratory and Hospital & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing burden of tuberculosis globally and need to diagnose at very early stage
    • 5.1.1.2. Increasing R&D investments and intensive diagnostics products in pipelines
    • 5.1.1.3. Supportive government initiatives and rising awareness in the emerging markets
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with tuberculosis diagnostics
    • 5.1.2.2. Limited reimbursement options
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising number of government awareness programs
    • 5.1.3.2. Advancement in the diagnostics procedures
  • 5.1.4. Challenges
    • 5.1.4.1. Low coverage or absence of insurance in emerging markets
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Tuberculosis Diagnostics Market, by Test Type

• 6.1. Introduction
• 6.2. Drug-susceptibility Testing
• 6.3. Laboratory Methods
• 6.4. Mantoux Test
• 6.5. Nucleic Acid Testing
• 6.6. Radiographic Methods

7. Tuberculosis Diagnostics Market, by Type

• 7.1. Introduction
• 7.2. Point-of-Care Technologies
• 7.3. Rapid Test

8. Tuberculosis Diagnostics Market, by End_User

• 8.1. Introduction
• 8.2. Diagnostics Research Laboratory
• 8.3. Hospital & Clinics

9. Americas Tuberculosis Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Tuberculosis Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Tuberculosis Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. ACON Laboratories, Inc.
• 3. Becton, Dickinson, and Company
• 4. bioMerieux SA
• 5. Bruker Corporation
• 6. Cepheid
• 7. Elisabeth Pharmacon, spol. s r.o.
• 8. ELITech Group
• 9. F. Hoffmann-La Roche AG
• 10. Hologic Corporation
• 11. OSANG HEALTHCARE CO., LTD
• 12. PerkinElmer, Inc.
• 13. Siemens AG
• 14. Thermo Fisher Scientific, Inc.
• 15. Turklab A.S.